RAG-21 utilizes RNA interference to selectively reduce FUS mRNA transcripts. This mechanism prevents the production of toxic FUS proteins and addresses the underlying pathology of FUS -ALS.

Tra Rags Petitions to Get Cast in ‘Scary Movie 6’: ‘I Need to Be in This' The Wayans brothers recently announced they're rebooting the beloved comedy franchise. Joe Price October 31, 2024 ...

Social media comedian Tra Rags recently linked up with the artist formerly known as Kanye West through FaceTime after the latter gave a shoutout to the internet personality. On Friday, an image of ...

Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances Apr. 09, 2025 8:00 AM ET ...

JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical ...

Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA (siRNA) therapy, RAG-17, for treating amyotrophic lateral sclerosis (ALS ...

RAG-17 received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in March 2023, followed by the FDA's clearance of its Investigational New Drug (IND) application.